New combo therapy targets hard-to-treat colorectal liver metastases
NCT ID NCT07544784
First seen Apr 23, 2026 · Last updated Apr 28, 2026 · Updated 2 times
Summary
This study tests whether adding the drug cadonilimab (AK104) and radiotherapy to standard chemotherapy improves outcomes for people with a common type of colorectal cancer that has spread to the liver. About 73 participants will be randomly assigned to receive either the new combination or standard therapy alone. The goal is to see if the combination shrinks tumors more effectively and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER LIVER METASTASES (CRLM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wenhua Li
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.